Stay updated on Pralsetinib in RET+ Cancer Clinical Trial

Sign up to get notified when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pralsetinib in RET+ Cancer Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    Locations section updated with new site entries across multiple US states (Arizona, California, Colorado, District of Columbia, Florida, Maryland, Massachusetts, Michigan, Minnesota, Missouri, New York, Oregon, Texas, Washington) and international regions (Emilia-Romagna, Lazio, Lombardy, Barcelona); some previously listed locations were removed.
    Difference
    1.0%
    Check dated 2025-12-17T20:08:14.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    35 days ago
    Change Detected
    Summary
    A note that publications are automatically filled from PubMed was added, and the revision label updated from v3.2.0 to v3.3.2.
    Difference
    0.1%
    Check dated 2025-11-26T08:31:45.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The page no longer displays a government funding status notice. Core trial details, enrollment status, eligibility criteria, and location information remain unchanged.
    Difference
    0.2%
    Check dated 2025-11-19T09:17:56.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    No significant changes detected between the old and new screenshots; the page content and layout appear unchanged.
    Difference
    0.2%
    Check dated 2025-10-28T13:22:13.000Z thumbnail image
  7. Check
    86 days ago
    Change Detected
    Summary
    Page now reflects a new release (v3.2.0) and an urgent operating-status notice due to funding gaps; an older resource topic (Medullary thyroid carcinoma) is removed.
    Difference
    1%
    Check dated 2025-10-06T04:22:19.000Z thumbnail image
  8. Check
    93 days ago
    Change Detected
    Summary
    Core term updated: 'Medullary thyroid gland carcinoma' → 'Medullary thyroid carcinoma'; page version updated from v3.0.2 to v3.1.0.
    Difference
    0.0%
    Check dated 2025-09-28T23:40:23.000Z thumbnail image

Stay in the know with updates to Pralsetinib in RET+ Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pralsetinib in RET+ Cancer Clinical Trial page.